NasdaqGS - Nasdaq Real Time Price
USD
Alnylam Pharmaceuticals, Inc. (ALNY)
296.11
-13.38
(-4.32%)
At close: May 1 at 4:00:01 PM EDT
303.66
+7.55
(+2.55%)
After hours: May 1 at 7:47:23 PM EDT
Trade ALNY on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for ALNY
- Previous Close
309.49 - Open
308.85 - Bid 295.76 x 200
- Ask 296.36 x 100
- Day's Range
295.79 - 311.88 - 52 Week Range
245.96 - 495.55 - Volume
1,115,819 - Avg. Volume
1,236,165 - Market Cap (intraday)
39.514B - Beta (5Y Monthly) --
- PE Ratio (TTM)
74.59 - EPS (TTM)
3.97 - Earnings Date (est.) Jul 30, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
449.48
Recent News: ALNY
View More
Performance Overview: ALNY
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ALNY
25.54%
S&P 500 (^GSPC)
5.62%
1-Year Return
ALNY
16.06%
S&P 500 (^GSPC)
29.01%
3-Year Return
ALNY
46.68%
S&P 500 (^GSPC)
73.47%
5-Year Return
ALNY
110.54%
S&P 500 (^GSPC)
72.92%
Earnings Trends: ALNY
View MoreAnalyst Insights: ALNY
View MoreStatistics: ALNY
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
39.51B
-
Enterprise Value
37.78B
-
Trailing P/E
74.40
-
Forward P/E
33.11
-
PEG Ratio (5yr expected)
0.59
-
Price/Sales (ttm)
9.45
-
Price/Book (mrq)
36.74
-
Enterprise Value/Revenue
8.81
-
Enterprise Value/EBITDA
43.64
Financial Highlights
Profitability and Income Statement
-
Profit Margin
12.55%
-
Return on Assets (ttm)
10.06%
-
Return on Equity (ttm)
90.36%
-
Revenue (ttm)
4.29B
-
Net Income Avi to Common (ttm)
537.99M
-
Diluted EPS (ttm)
3.97
Balance Sheet and Cash Flow
-
Total Cash (mrq)
3.01B
-
Total Debt/Equity (mrq)
276.20%
-
Levered Free Cash Flow (ttm)
191.27M
Compare To: ALNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: ALNY
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: ALNY
View More-
Alnylam Earnings: Amvuttra Uptake Drives Sales; Durability of Demand in Focus Amid Competition
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target -
Narrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target -
Daily – Vickers Top Buyers & Sellers for 02/18/2026
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
-
Alnylam Earnings: Milestone Year as Firm Turned Profitable; Demand for Amvuttra Drives Growth
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
RatingPrice Target
